RecruitingNCT07182474

Turkish Version of the BRIEF-Hammersmith Infant Neurological Examination (HINE)

Turkish Version of the BRIEF-Hammersmith Infant Neurological Examination (HINE) With Infants at Risk: A Study of Validity and Reliability


Sponsor

Kahramanmaras Sutcu Imam University

Enrollment

120 participants

Start Date

Aug 22, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The American Academy of Pediatrics defines infants at risk as those with preterm birth, special health care needs, family risk factors, and those at risk of early death. Factors such as premature birth, perinatal asphyxia, hypoxic-ischemic encephalopathy (HIE), periventricular leukomalacia (PVL), intraventricular hemorrhage (IVH), chronic lung disease, seizures, meningitis, hyperbilirubinemia, twin/triplet pregnancy, and intrauterine growth restriction are risk factors that can result in morbidity and mortality in infants. Regular neurological examinations and neuromotor tests are necessary for at-risk infants to identify developmental problems early and to initiate early intervention programs.In developing countries, regular follow-up and early rehabilitation of at-risk infants are not successfully implemented. 5,6 The lengthy test batteries and busy clinics are among the most significant reasons. Therefore, the development and dissemination of shorter, valid, and reliable tests is of great importance. The Hammersmith Neonatal Neurological Examination (HINE), one of the gold standard methods, consists of 26 items and takes 15-20 minutes to administer.Due to the number of items and the duration, it is not frequently used routinely. In response to this clinical need, the HINE short scale was developed in 2024.The aim of the study is to have a Turkish version of the Abstract-HINE test in Turkey and to study its validity and reliability in infants at risk.


Eligibility

Min Age: 3 MonthsMax Age: 12 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with neurodevelopment outcome, neurological abnormality, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 3 Months to 12 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Kahramanmaraş Sütçü imam University

Kahramanmaraş, Onikişubat, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07182474


Related Trials